<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04032353</url>
  </required_header>
  <id_info>
    <org_study_id>2019SDU-QILU-150</org_study_id>
    <nct_id>NCT04032353</nct_id>
  </id_info>
  <brief_title>Medical Consortium for Screening Upper Gastrointestinal Cancers With Magnetically Controlled Capsule Gastroscopy</brief_title>
  <official_title>Medical Consortium for Screening Upper Gastrointestinal Cancers With Magnetically Controlled Capsule Gastroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yanqing Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study was to demonstrate the efficacy and feasibility of the medical
      consortium for screening upper gastrointestinal cancers with magnetically controlled capsule
      gastroscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators designed a propective cohort study to evaluate the the
      efficacy and feasibility of medical consortium for screening upper gastrointestinal cancers
      (MCSC) with magnetically controlled capsule gastroscopy (MCCG).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 31, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the incidence of upper gastrointestinal cancers, including gastric cancer and esophageal cancer.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tthe focal lesions of upper gastrointestinal tract</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>safety assessment</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Capsule Endoscopy</condition>
  <condition>Cancer of Stomach</condition>
  <condition>Cancer of Esophagus</condition>
  <condition>Health Policy</condition>
  <arm_group>
    <arm_group_label>Medical Consortium</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>subjects involved in medical consortium for screening upper gastrointestinal canccers(MCSC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical Consortium</intervention_name>
    <description>subjects received intensive follow-up by coordinators according to the predifined protocol of MCSC</description>
    <arm_group_label>Medical Consortium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  asymptomatic subjects undergong magnetically controlled capsule gastroscopy for health
             checkup in medical consotium;

          -  subjects able to give informed consent

        Exclusion Criteria:

          -  suspected or known intestinal stenosis, obstruction, or fistula;

          -  inoperability of refusal to accept any abdominal surgery;

          -  dysphagia or gastric paralysis;

          -  previous history of gastrointestinal disease;

          -  with pacemaker, implanted-cardiac defibrillator or other implanted electromedical
             devices;

          -  need for standard magnetic resonance imaging examination within seven days after
             swallowing the MCCG, unless the capsule is confirmed to have been excreted;

          -  other factors that are not suitable for inclusion evaluated by medical stuff
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yanqing Li, PhD, MD</last_name>
    <phone>86-531-82169236</phone>
    <email>liyanqing@sdu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Gastroenterology, Qilu Hospital, Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanqing Li, PHD</last_name>
      <phone>86-531-82169236</phone>
      <email>liyanqing@sdu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 23, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2019</study_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Yanqing Li</investigator_full_name>
    <investigator_title>vice president of Qilu Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

